Davis's Drug Guide
mirdametinib
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
mir-da-me-ti-nib
Trade Name(s)
- Gomekli
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Mirdametinib." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. www.drugguide.com/ddo/view/Davis-Drug-Guide/3580218/all/mirdametinib.
Vallerand AHA, Sanoski CAC. Mirdametinib. Davis's Drug Guide. F.A. Davis Company; 2026. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/3580218/all/mirdametinib. Accessed October 15, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Mirdametinib. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/3580218/all/mirdametinib
Vallerand AHA, Sanoski CAC. Mirdametinib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 October 15]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/3580218/all/mirdametinib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - mirdametinib
ID - 3580218
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/3580218/all/mirdametinib
PB - F.A. Davis Company
ET - 20
DB - Davis's Drug Guide
DP - Unbound Medicine
ER -